Cargando…

Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling

We designed a mathematical model to describe and quantify the mechanisms and dynamics of tumor growth, cell-kill and resistance as they affect durations of benefit after cancer treatment. Our aim was to explore how treatment efficacy may be related to primary tumor characteristics, with the potentia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gregory, Walter M., Twelves, Christopher J., Bell, Richard, Smye, Stephen W., Howard, Dena R., Coleman, Robert E., Cameron, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2016
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729810/ https://www.ncbi.nlm.nih.gov/pubmed/26783036 http://dx.doi.org/10.1007/s10549-016-3684-4

Ejemplares similares

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
por: Oswald, Ailsa J., et al.
Publicado: (2023)

Factors affecting the number of sentinel lymph nodes removed in patients having surgery for breast cancer
por: Dixon, J. Michael, et al.
Publicado: (2020)

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
por: Twelves, Chris, et al.
Publicado: (2014)

Modelling residual disease volume and re-growth rates from response durations to aid in cancer trial design, interpretation and analysis, with a particular focus on breast cancer
por: Gregory, Walter, et al.
Publicado: (2013)

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial
por: Cortes, Javier, et al.
Publicado: (2015)

A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease
por: Coleman, Robert, et al.
Publicado: (2014)

Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
por: Agersborg, Sally, et al.
Publicado: (2018)

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
por: Cortés, Javier, et al.
Publicado: (2017)

Preventative therapy for breast cancer: a clinical experience
por: Law, Rebekah, et al.
Publicado: (2023)

Multiparametric radiomics methods for breast cancer tissue characterization using radiological imaging
por: Parekh, Vishwa S., et al.
Publicado: (2020)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

Impact of primary breast cancer therapy on energetic capacity and body composition
por: Ballinger, Tarah J., et al.
Publicado: (2018)

Conventional specimen radiography in breast-conserving therapy: a useful tool for intraoperative margin assessment after neoadjuvant therapy?
por: Schäfgen, Benedikt, et al.
Publicado: (2023)

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
por: Blok, Erik J., et al.
Publicado: (2017)

HER2-targeted therapy influences CTC status in metastatic breast cancer
por: Deutsch, Thomas M., et al.
Publicado: (2020)

Taste and smell perception and quality of life during and after systemic therapy for breast cancer
por: de Vries, Y. C., et al.
Publicado: (2018)

Systemic therapy following craniotomy in patients with a solitary breast cancer brain metastasis
por: Hulsbergen, Alexander F. C., et al.
Publicado: (2020)

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events
por: Addison, Christina L., et al.
Publicado: (2014)

Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
por: Taylor, Caitlin, et al.
Publicado: (2023)

Patients Offer Radiofrequency Ablation Therapy for Early Breast Cancer as Local Therapy (PO-RAFAELO) Study under the Patient-proposed Health Services
por: Takayama, Shin, et al.
Publicado: (2023)

Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy
por: van Roozendaal, L. M., et al.
Publicado: (2016)

The impact of hyperbaric oxygen therapy on late radiation toxicity and quality of life in breast cancer patients
por: Batenburg, Marilot C. T., et al.
Publicado: (2021)

Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer
por: Skarping, Ida, et al.
Publicado: (2021)

Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer
por: Sanft, Tara, et al.
Publicado: (2015)

Aesthetic result after breast-conserving therapy is associated with quality of life several years after treatment. Swedish women evaluated with BCCT.core and BREAST-Q™
por: Dahlbäck, Cecilia, et al.
Publicado: (2017)

Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer
por: Helbrich, H., et al.
Publicado: (2021)

Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer
por: Lemij, Annelieke A., et al.
Publicado: (2022)

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer
por: Wilson, Florence R., et al.
Publicado: (2017)

Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients
por: Nteliopoulos, Georgios, et al.
Publicado: (2021)

Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2
por: Beck, J. Thaddeus, et al.
Publicado: (2013)

Repeat breast-conserving treatment of ipsilateral breast cancer recurrence: a nationwide survey amongst breast surgeons and radiation oncologists in the Netherlands
por: Walstra, Coco J. E. F., et al.
Publicado: (2021)

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
por: Wardley, Andrew, et al.
Publicado: (2021)

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
por: Yu, Y. F., et al.
Publicado: (2017)

Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer
por: Goncalves, Rodrigo, et al.
Publicado: (2017)

Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments
por: Reis, Joana, et al.
Publicado: (2020)

Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes and quality of life
por: Wyld, Lynda, et al.
Publicado: (2021)

Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study
por: Pan, Yiqi, et al.
Publicado: (2018)

The potential role of three-dimensional surface imaging as a tool to evaluate aesthetic outcome after Breast Conserving Therapy (BCT)
por: O’Connell, Rachel L., et al.
Publicado: (2017)

Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey
por: McGee, Sharon, et al.
Publicado: (2021)

Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
por: Tausch, Christoph, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nei2fq9qgkkdqub324jcrem6e6